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Abstract
Background: Plasma levels of tumor necrosis factor (TNF)-α and of C-reactive protein (CRP) are
elevated in smokers. Previous studies failed to show an association between the G-308A
polymorphism in the promoter region of the TNF-α gene and coronary artery disease (CAD). We
investigated whether smoking would interact with the TNF-α G-308A polymorphism in
determining plasma levels of TNF-α and CRP.
Methods: Study participants with a complete data set in terms of smoking and the TNF-α G-308A
polymorphism were 300 middle-aged male and female industrial employees. After excluding 24
irregular smokers, analyses were performed on 198 "non-smokers" (life-long non-smokers or
subjects who quit smoking >6 months ago) as compared to 78 "regular smokers" (subjects
currently smoking >3 cigarettes/day). All subjects had a fasting morning blood draw to measure
plasma levels of TNF-α and CRP by high-sensitive enzyme-linked immunosorbent assays.
Results: The cardiovascular risk factor adjusted analysis regressing log-transformed CRP levels
against smoking status, genotype, and smoking-status-genotype interaction revealed a significant
main effect for smoking status (F1,250 = 5.67, p = .018) but not for genotype (F1,250 = 0.33, p = .57).
The interaction-term between genotype and smoking status was not significant (F1,250 = 0.09, p =
.76). The fully adjusted model with plasma TNF-α failed to show significant main effects for smoking
and genotype, as well as for the smoking-status-genotype interaction.
Conclusions: The findings suggest that the TNF-α G-308A polymorphism does not mediate the
effect of smoking on plasma CRP levels. It remains to be seen whether other genetic
polymorphisms along the inflammatory pathway may modulate vascular risk in smokers.
Background
Coronary artery disease (CAD) is associated with chronic
inflammatory processes in which blood-derived macro-
phages play a key role [1]. Tumor necrosis factor (TNF)-α
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is essentially produced by monocytes and macrophages,
and, in turn, it is the strongest known paracrine activator
of monocytes and macrophages [2]. Upon stimulation,
these cells secrete a variety of products including inter-
leukin (IL)-6 stimulating the liver to produce the acute
phase reactant C-reactive protein (CRP) [3]. CRP is an
acknowledged indicator of increased systemic inflamma-
tion across a wide range of diseases [4]. TNF-α and CRP
both are found in considerable quantities in atheroscle-
rotic lesions [5,6], and they have also been associated with
increased cardiovascular risk in numerous large popula-
tion-based studies [[7,8]; for review].
Smoking is one of the strongest cardiovascular risk factors
for atherosclerotic diseases [9]. Several studies have
revealed increased plasma levels of TNF-α and of CRP in
smokers as compared to non-smokers [10,11], suggesting
that part of the coronary risk associated with smoking may
relate to increased inflammatory activity. However, the
prevalence of cardiovascular disease varies substantially
among smoking individuals [12]. This could indicate that
genetic factors are important determinants of the biologi-
cal pathways linking smoking with cardiovascular disease
risk [13]. In fact, it has been recently shown that the CC
polymorphism in the promoter region of the CD14 gene
(CD14 -159C/T) was associated with common carotid
artery intima-media thickness in smokers, but not in non-
smokers [14]. Similarly, in young and healthy individuals
carrying the C allele of the interleukin-6 promoter poly-
morphism -174 genotype, those who smoked had higher
leukocytes, lymphocytes, and monocytes than those who
did not smoke [15].
Another candidate polymorphism that might mediate the
cardiovascular risk with smoking, and that is at the initia-
tion of the inflammatory cascade, is the G-308A polymor-
phism of the TNF-α gene promoter site. The TNF-α G-
308A polymorphism is a single base pair polymorphism
located at position 308 in the TNF-α gene that maps to
human chromosome 6 (p21.1-p21.3) resulting in substi-
tution of the nucleotide adenine (A) for guanine (G) [16].
In the present study, we investigated the possible impact
of this polymorphism on the association between smok-
ing severity and plasma levels of TNF-α and CRP in vivo.
While the TNF-α G-308A polymorphism has been associ-
ated with increased production of TNF-α in vitro [17,18],
previous studies failed to show an association of this pol-
ymorphism with CAD [19-25]. However, there is a dearth
of data regarding possible interactions between environ-
mental risk factors for cardiovascular disease (e.g., smok-
ing) and the G-308A polymorphism on plasma levels of
proinflammatory markers. It is conceivable that the TNF-
α G-308A polymorphism alone is of negligible impor-
tance in CAD, but that the presence of certain environ-
mental conditions (i.e., exposure to tobacco smoke) and
specific alleles may influence CAD risk [26-28].
If alleles are randomly distributed between smokers and
non-smokers, case-control studies not explicitly investi-
gating the possible environmental-genetic interaction
might fail to unravel the role of genetic polymorphisms in
CAD. Therefore, we speculated that smoking would affect
plasma TNF-α and CRP levels depending on the TNF-α
genotype. If so, the genotype might affect the rate of dis-
ease progression rather than the existence of atheroscle-
rotic lesions.
Methods
Study participants
The study was conducted as part of a larger project in an
airplane manufacturing plant in southern Germany. From
a total of 1,760 employees, participation was offered to a
representative sample of 647 men and women. Of those,
537 (accrual rate 83%) volunteered to participate. The
Institutional Review Board approved the study protocol.
All 537 subjects completed questionnaires on medical
and psychosocial health status. A subsample of 332 sub-
jects agreed to have a variety of biological measures
assessed. Three hundred of these individuals had com-
plete data on smoking status, smoking history and the
TNF-α G-308A gene polymorphism.
Based on self-reported smoking history, we categorized
life-long non-smokers or those, who had quit smoking for
at least 6 months as „non-smokers" (n = 198), smokers
who were currently smoking >3 cigarettes per day as "reg-
ular smokers" (n = 78), and smokers reporting to con-
sume up to 3 cigarettes/day or who had stopped smoking
for less than 6 months as „irregular smokers" (n = 24).
Because of the resulting small numbers of irregular smok-
ers, the latter 24 individuals were excluded from further
analyses. Of the remaining 276 individuals, we excluded
those with a history suggestive of symptomatic atheroscle-
rotic disease, individuals reporting intake of drugs or con-
ditions that might affect CRP levels (including chronic
inflammatory diseases such as active rheumatoid arthri-
tis), and subjects for whom CRP data were missing
because of occasional assay problems. Subjects reporting
a positive history of elevated blood glucose were not
excluded. This selection procedure resulted in a final data-
set of 261 subjects.
Experimental protocol
Data were collected on two occasions: First, subjects com-
pleted a medical questionnaire and examination. The
medical assessment consisted of a 96-item questionnaire
assessing the medical history and smoking behavior. The
questionnaire was based on the Nurses Health Study [29]BMC Cardiovascular Disorders 2004, 4:17 http://www.biomedcentral.com/1471-2261/4/17
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with questions asking for smoking behavior adapted from
the MONICA study [30].
After completion of questionnaires, subjects had a 15-min
rest period while sitting. Thereafter, systolic and diastolic
blood pressure (BP) were measured twice within 5 min by
sphygmomanometry, and the average of the two readings
was computed. The waist-to-hip ratio was calculated
based on waist circumference (as measured at its narrow-
est point between the ribs and iliac crest) and hip circum-
ference (as measured at the maximal buttocks). Blood
samples after overnight fasting were collected within one
day to two weeks after having obtained medical data.
Blood sampling was scheduled two hours after awakening
to minimize circadian variation in variables of interest.
Biochemical analyses
Venous blood was obtained using cooled (4°C) citrate
tubes for the TNF-α assay. Plasma was snap-frozen after
centrifugation until further processing. We chose high-
sensitive enzyme-linked immunosorbent assays (ELISA)
to measure plasma concentrations of TNF-α (Quantikine
HS, R&D Systems Europe, Abington, United Kingdom)
and of CRP (detection limit 0.1 mg/l; Immunolite, DPC
Biermann GmbH, Germany). In contrast to standard CRP
assays, the high-sensitivity assay for CRP allows stratifica-
tion of subjects with CRP levels below the range used for
infectious disease workup [31]. Moreover, it has been
argued that the high-sensitive CRP assay is required for
risk assessment of cardiovascular disease [32]. Low-den-
sity lipoprotein cholesterol (LDL-C) cholesterol and high-
density lipoprotein cholesterol (HDL-C) as well as hemo-
globin A1c (HbA1c) were determined by a commercial
laboratory (Synlab, Augsburg, Germany) applying stand-
ard procedures.
Gene analysis
To determine the TNF-α -308 G/A gene polymorphism,
we extracted genomic DNA from the leukocyte-containing
pellets remaining after centrifugation of coagulated blood
using the QIAmp DNA Blood Mini Kit (Qiagen, Hilden,
Germany). The TNF-α G-308A polymorphism was
assessed by fluorescent real-time polymerase chain reac-
tion with melting curve analysis on a LightCycler (Roche
Diagnostics, Rotkreuz, Switzerland) using the TNF-α G-
308A ToolSet for LightCycler (Genes-4U, Neftenbach,
Switzerland) containing specific primers and fluorescent
mutation detection oligonucleotide probes, in conjunc-
tion with the Roche Light Cycler Hyb Probe Master Mix
(Roche Diagnostics, Rotkreuz, Switzerland) according to
the manufacturer's protocols. For statistical analyses, we
used the following groups: a) the GG variant, and b) the
rarer AA and GA genotypes combined.
Statistical analyses
Descriptive data are presented as means ± SD or as median
and interquartile range for severely skewed data. To
approximate a normal distribution, we log transformed
TNF-α and CRP values. General linear models were
employed to elucidate the proportion of variance
explained of log-transformed plasma TNF-α and CRP val-
ues (dependent variables). Independent variables were
smoking status (regular smokers vs. non-smokers), gene
variant, and an interaction term between smoking status
and gene variant. Following this crude analysis, we
entered possible covariates (age, gender, self-reported
physical exercise, self-reported alcohol intake, gender, BP,
and lipoproteins) into the equation. Results were consid-
ered statistically significant at the p ≤ .05 level; all tests
were 2-tailed. To minimize possible type II errors when
assessing interaction terms, we considered interaction
terms when the F-statistic on the interaction term had a p-
value < 0.2 [33]. All regression and variance analyses were
performed using generalized linear models (PROC
MIXED) to account for the unbalanced nature of the data
(SAS version 8.2, SAS Inc, Cary, NC). Analyses were
repeated including the small group (n = 24) of irregular
smokers either with the non-smokers or with the regular
smokers. None of these additional analyses changed our
main results to a relevant degree. Therefore, only the
results comparing non-smokers with regular smokers are
reported.
Results
Study population and smoking status
Table 1 compares health variables between non-smokers
(n = 198), irregular smokers (n = 24) and regular smokers
(n = 78). Regular smokers tended to be younger (p =
0.09), and they had significantly lower HDL-C levels (p =
0.01) than non-smokers. Regular smokers also had higher
plasma levels of CRP than non-smokers (median 1.75
mg/l vs. 1.0 mg/l, p = 0.006). In our study sample, irregu-
lar smokers had plasma levels of CRP comparable to non-
smokers (median 0.81 vs. 1.0 mg/l, p = 0.94). TNF-α was
not significantly different between regular smokers and
non-smokers.
Gene distribution
After excluding irregular smokers, we found the GG wild
type polymorphism in 203 subjects (74%); GA heterozy-
gote were 70 participants (25%) and AA homozygote
were 3 participants (1%). Calculated allele frequencies
amounted to 0.86 for the G allele and to 0.14 for the A
allele. Regular smokers were slightly though not signifi-
cantly more frequent amongst subjects with the GG geno-
type than amongst individuals carrying the GA or AA
genotype (odds ratio 1.41; 95% CI 0.77–2.6, p = 0.26).
Table 2 compares individuals with the GG wild type with
participants having the GA or the AA genotype. The tableBMC Cardiovascular Disorders 2004, 4:17 http://www.biomedcentral.com/1471-2261/4/17
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reveals that genotype was not associated with any of the
examined health variables in crude bivariate compari-
sons, including plasma levels of TNF-α and CRP.
Genotype, smoking status, TNF-α and CRP levels
The adjusted analysis regressing log-transformed CRP lev-
els against smoking status, genotype, and smoking-status-
genotype interaction revealed a main effect for smoking
status (F1,250 = 5.67, p = .018), but not for genotype (F1,250
= 0.33, p = .57). The interaction-term between genotype
and smoking status failed to gain significance (F1,250 =
0.09, p = .76), indicating that the effect of smoking on
plasma levels of CRP is not affected by the TNF-α -308G/
A polymorphism (Figure). Of the considered covariates,
gender (F1,250 = 12.5, p = .0005), age (F1,250 = 4.55, p =
.03), and HDL-C (F1,250 = 3.4, p = .065) were associated
with CRP levels, but not BP or LDL-C. Men, older individ-
uals, and those with lower HDL-C had higher plasma lev-
els of CRP.
The fully adjusted model with plasma levels of TNF-α also
failed to show significant main effects for genotype (F1,246
= 1.08, p = .30) and for smoking (F1,246 = 0.33, p = .56), as
well as for the smoking-status-genotype interaction. How-
ever, the adjusted model revealed a significant main effect
for HDL-C (F1,246 = 20.7, p < .0001), suggesting that indi-
viduals with higher plasma levels of TNF-α had lower
HDL-C. Post-hoc analyses revealed no interaction
between smoking status and HDL-C or genotype and
HDL-C.
Table 1: Subject characteristics in relation to smoking status
Smoking status
Variable Non-smokers for >6 months 
n = 198
Irregular smokers 
n = 24
Regular smokers 
n = 78
P-valuea
Gender [% male] 86 80 88 0.52
Age [years] 42.1 ± 9.0 40.6 ± 9.2 40.0 ± 9.6 0.09
LDL [mg/dl] 122.3 ± 28.5 117.4 ± 30.4 115.9 ± 28.3 0.10
HDL [mg/dl] 45.3 ± 10.8 47.1 ± 8.3 41.4 ± 9.2 0.01
Systolic blood pressure [mmHg] 132.9 ± 15.2 128.7 ± 9.9 131.2 ± 13.6 0.43
Diastolic blood pressure [mmHg] 82.9 ± 9.7 79.2 ± 8.0 81.6 ± 8.3 0.33
Glycosylated hemoglobin [%] 5.15 ± 0.5 5.1 ± 0.4 5.25 ± 0.4 0.12
Tumor necrosis factor-α [ng/l] 1.8 ± 0.5 1.8 ± 1.0 2.2 ± 2.5 0.61
C-reactive protein [mg/l] 1.0 (0.47–1.9) 0.80 (0.5–2.0) 1.75 (0.7–3.0) 0.006
a P-values for comparisons between non-smokers and regular smokers. Tumor necrosis factor-α and C-reactive protein (CRP) levels were 
compared using the Wilcoxon test; for all other continuous variables the Student t-test was employed. Values are means ± SD except for CRP 
where the median and interquartile range is provided. LDL = Low-density lipoprotein cholesterol, HDL = High-density lipoprotein cholesterol
Table 2: Subject characteristics in relation to the TNF-α G-308 polymorphism
GG n = 203 GA/AA n = 73 P-value
Gender [% male] 87 86 0.73
Age [years] 41.0 ± 9.1 42.9 ± 9.4 0.37
Regular smokers [%] 28.3 21.8 0.26
Low-density lipoprotein cholesterol [mg/dl] 119.5 ± 32.6 124.8 ± 29.1 0.22
High-density lipoprotein cholesterol [mg/dl] 44.1 ± 11.9 44.62 ± 10.9 0.76
Systolic blood pressure [mmHg] 131.7 ± 11.7 134.6 ± 17.4 0.18
Diastolic blood pressure [mmHg] 82.5 ± 11.1 82.7 ± 8.1 0.87
Glycosylated hemoglobin A1c [%] 5.1 ± 0.5 5.2 ± 0.6 0.18
Tumor necrosis factor-α [ng/l] 1.7 (1.3–2.2) 1.9 (1.4–2.2) 0.39
C-reactive protein [mg/l] 1.04 (0.53–2.36) 1.05 (0.49–3.14) 0.35
Tumor necrosis factor (TNF)-α and C-reactive protein (CRP) levels were compared by the Wilcoxon test; for all other continuous variables the 
Student t-test was employed. Values are means ± SD except for TNF-α and CRP where the median and interquartile range is provided.BMC Cardiovascular Disorders 2004, 4:17 http://www.biomedcentral.com/1471-2261/4/17
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Discussion
Genes, health-behavior and the psychosocial environ-
ment interact to determine whether or not, and, if at all,
how rapidly silent atherosclerosis will progress to the clin-
ical manifestation of CAD [34,35]. The development of
coronary artery sclerosis is a life-long process that proba-
bly has its onset in childhood [36]. Particularly, as sug-
gested by post mortem studies, inflammation-related
endothelial damage plays an important role in atheroscle-
rosis onset and progression early in life [37]. The under-
standing of atherosclerosis as an inflammatory disease [1]
has kindled much interest in a number of genetic
polymorphisms coding for inflammatory molecules
potentially related to CAD [38].
While plasma levels of the proinflammatory cytokine
TNF-α are regulated by several polymorphisms of the
TNF-α gene [39], it is the TNF-α G-308A gene polymor-
phism which has been most intensely scrutinized as one
candidate polymorphism underlying CAD [8]. Plasma
TNF-α levels predicted second myocardial infarction [40],
and have been associated with common carotid intima-
media thickness [41]. TNF-α also stimulates the liver to
produce CRP [8], which, itself, has been shown to predict
coronary risk in numerous population based studies [7].
Interestingly, blood cells from individuals who carry the A
allele of the TNF-α G-308A gene polymorphism express
more TNF-α in vitro upon stimulation with lipopolysac-
charide than cells from individuals being homozygous for
the G allele [18]. Despite this association, several studies
did not find a significant association between the TNF-α
G-308A gene polymorphism and incident CAD [19-25].
There are, however, no studies examining whether estab-
lished cardiovascular risk factors might interact with the
TNF-α G-308A gene polymorphism in determining
plasma levels of TNF-α and eventually CRP downstream
in the inflammatory cascade. We thus investigated the
effect of an interaction between smoking severity and the
G-308A polymorphism of the TNF-α gene on plasma lev-
els of these two proinflammatory markers. Our specific
hypothesis was that there was a cumulative increase of
The figure depicts plasma levels of C-reactive protein (CRP) in relation to smoking status and the TNF-α G-308 polymorphism  in the final sample of 261 subjects Figure 1
The figure depicts plasma levels of C-reactive protein (CRP) in relation to smoking status and the TNF-α G-308 polymorphism 
in the final sample of 261 subjects. CRP levels are anti-log transformed least square means estimates from the fully adjusted 
model controlling for age, gender, blood pressure and blood lipids. Error bars denote the standard error of the mean estimate. 
Simple effects comparing genotypes across smokers were not significant (p = .14).
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TNF-α and CRP related to the TNF-α G-308A polymor-
phism in subjects who regularly smoke as compared to
non-smokers.
In spite of two recent studies, which found an interaction
between smoking and polymorphisms of molecules par-
ticipating in the inflammatory response [14,15], the
results from the present study fail to support our hypoth-
esis. More precisely, we found that the interaction
between smoking status and the TNF-α G-308A polymor-
phism did not significantly affect plasma levels of TNF-α
and CRP in both unadjusted and adjusted analyses. Also,
there was no main effect for the polymorphism investi-
gated in terms of plasma levels of TNF-α and CRP. On the
other hand, although not an aim of our study, we con-
firmed previous findings of increased plasma CRP in reg-
ular smokers as compared to non-smokers [11], while,
rather unexpectedly, plasma levels of TNF-α were not dif-
ferent between smokers and non-smokers.
It must be noted that our findings are preliminary, and,
they do not allow us to reject the overall hypothesis of a
smoking-gene interaction modifying inflammatory proc-
esses contributing to atherosclerosis initiation and pro-
gression [14,15]. For instance, because the number of
homozygous carriers of the A allele in our study popula-
tion was low reflecting low frequency of the AA genotype
in the general population, we were unable to analyze
whether there might be a "dose-response" relationship
between the A allele dosage and CRP levels. Larger sample
sizes are clearly needed to detect a potential difference in
regulation of proinflammatory markers in plasma across
the GG, AG, and AA polymorphism and with respect to
their interaction with different cardiovascular risk factors.
This reasoning becomes even more obvious with respect
to the higher absolute difference in the mean estimates of
plasma CRP levels between the GG and the GA/AA geno-
types in smokers as compared to non-smokers (Figure). A
highly powered study might raise the odds of this absolute
difference to become statistically significant. Moreover,
the biological plausibility of our hypothesis was straight-
forward given the important role of smoking, inflamma-
tion and their link in CAD [9-11]. However, we do not
know in how far interactions between smoking, the TNF-
α G-308A polymorphism, and other polymorphisms of
molecules involved in the inflammatory pathways not
investigated in our study [14,15] might affect plasma TNF-
α and CRP levels in an unexpected way.
The lack of a difference in plasma TNF-α levels between
subjects with the A allele as compared to those
homozygous for the G allele stands in contrast to previous
in vitro studies [17,18]. However, aside from a power
issue, our measured values of TNF-α levels only slightly
exceeded the assay's sensitivity limit, incurring a larger
chance of measurement error. We may speculate that a
relation between gene variant, smoking, and circulating
TNF-α levels might have been uncovered among patients
with atherothrombotic disorders or other inflammatory
conditions. Moreover, we measured systemic TNF-α; cir-
culating TNF-α may not necessarily reflect TNF-α secre-
tion at sites of confined subendothelial atherosclerotic
lesions, where regulatory polymorphisms are most likely
to affect reactions of immune cells. Finally, interactions
also involving IL-6 polymorphisms [15] may play a role in
the association between smoking, elevated CRP, and
increased CAD risk. Future studies thus may want to inves-
tigate whether IL-6 polymorphisms might be associated
with plasma CRP levels and whether they interact with
TNF-α and CRP in smokers.
Conclusions
Our study suggests that both plasma TNF-α and CRP lev-
els are not regulated by an interaction between smoking
and the G-308A polymorphisms of the TNF-α gene pro-
moter site. We thus remain far from adopting a clinical
practice that would counsel smokers to quit smoking
based on a particular gene polymorphism. Nonetheless,
our results do not refute the overall hypothesis that
genetic polymorphisms along the inflammatory pathway
may account for the differential effect of tobacco con-
sumption on the cardiovascular risk in individuals who
smoke.
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